Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 16, 2008

TaiGen : Positive Data From the Phase II Study of Nemonoxacin (TG-873870) in Community-Acquired Pneumonia

2008/04/07 - -TaiGen Biotechnology Co., Ltd. announced today that the nemonoxacin phase II top-line data in community-acquired pneumonia (CAP) met the primary endpoint of non-inferiority versus levofloxacin, the leading quinolone on the market. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and gram-negative bacteria and atypical pathogens. Importantly, nemonoxacin possesses the first-in-class activity against MRSA (both hospital- and community-acquired) and vancomycin-resistant pathogens... TaiGen Biotechnology's Press Release -